97402 20210902121839.0 doi 10.1088/1748-605X/aba445 sideral 121787 ART-2020-121787 eng Prieto, E. Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation 2020 Access copy available to the general public Unrestricted This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier - DEX/LAP 1:10 w w-1 formulation; 10 mg ml-1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml-1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1-4-12-24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues'' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g-1 d-1) than after IV administration of the DEX solution (317.17 ng g-1 d-1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 311.15 ng g-1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 20.85 ng g-1) and sclera (25.46 44.09 ng g-1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases. info:eu-repo/grantAgreement/ES/DGA/E37-17R info:eu-repo/grantAgreement/ES/DGA-FEDER/Construyendo Europa desde Aragón info:eu-repo/grantAgreement/ES/ISCIII/M17-00213 info:eu-repo/grantAgreement/ES/ISCIII/PI12-02285 info:eu-repo/grantAgreement/ES/ISCIII/PI17-01726 info:eu-repo/grantAgreement/ES/ISCIII/PI17-01946 info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 3.715 2020 ENGINEERING, BIOMEDICAL 39 / 90 = 0.433 2020 Q2 T2 MATERIALS SCIENCE, BIOMATERIALS 24 / 40 = 0.6 2020 Q3 T2 0.743 2020 Bioengineering 2020 Q1 Biomaterials 2020 Q1 Mechanics of Materials 2020 Q1 Business and International Management 2020 Q1 Chemistry (miscellaneous) 2020 Q1 Biomedical Engineering 2020 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Cardiel, M.J. Universidad de Zaragoza (orcid)0000-0002-7914-4685 Vispe, E. (orcid)0000-0002-4921-4734 Idoipe, M. Garcia-Martin, E. Universidad de Zaragoza (orcid)0000-0001-6258-2489 Fraile, J.M. Universidad de Zaragoza (orcid)0000-0002-0136-5138 Polo, V. Universidad de Zaragoza (orcid)0000-0002-1402-3129 Mayoral, J.A. Universidad de Zaragoza (orcid)0000-0003-1570-4257 Pablo, L.E. Universidad de Zaragoza (orcid)0000-0003-2389-8282 Rodrigo, M.J. 2013 765 Universidad de Zaragoza Dpto. Química Orgánica Área Química Orgánica 1013 646 Universidad de Zaragoza Dpto. Cirugía Área Oftalmología 1013 020 Universidad de Zaragoza Dpto. Cirugía Área Anatomía Patológica 15, 6 (2020), 065021 [14 pp] Biomedical Materials Biomedical Materials 1748-6041 503394 http://zaguan.unizar.es/record/97402/files/texto_completo.pdf Versión publicada 92307 http://zaguan.unizar.es/record/97402/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:97402 articulos driver 2021-09-02-10:22:31 ARTICLE